secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001823239-26-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance
---------------------------------------------------------------------------

- Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
- Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.
- TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.
- Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.
- Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/0001823239-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/mrvi-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001823239-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer